Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 18/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 18/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 18/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24352439 | 1.00 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CESR1ESR2 | |
| SCHEMBL188069 | 0.83 | ADRA2C (0.56) | ADRA2AADRA2BADRA2CESR1ESR2 | |
| SCHEMBL17897287 | 0.83 | ADRA2A (0.52) | ADRA2AADRA2BADRA2CESR1ESR2 | |
| SCHEMBL188214 | 0.83 | ADRA2C (0.56) | ADRA2AADRA2BADRA2CESR1ESR2 | |
| SCHEMBL15858055 | 0.83 | ADRA2A (0.52) | ADRA2AADRA2BADRA2CESR1ESR2 | |
| SCHEMBL1814699 | 0.83 | ADRA2C (0.56) | ADRA2AADRA2BADRA2CESR1ESR2 | |
| SCHEMBL14923974 | 0.82 | L3MBTL1 (0.46) | L3MBTL1 | |
| SCHEMBL23544859 | 0.82 | L3MBTL1 (0.46) | L3MBTL1 | |
| SCHEMBL23544861 | 0.82 | L3MBTL1 (0.46) | L3MBTL1 | |
| SCHEMBL81498 | 0.81 | ADRA2A (0.52) | ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | ADRA2A 4765/4885ADRA2B 4696/4885ADRA2C 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.